The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,057,905 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Regents of the University of Minnesota. The award, with a period of performance from April 15, 2025 to March 31, 2032, will support a comprehensive research program to promote weight-related health and address social determinants among the next generation of adolescents and young adults (Generation Z). Key elements of the program include...
This National Heart, Lung, and Blood Institute (NHLBI) Project Grant award under CFDA 93.837 Cardiovascular Diseases Research provides $1,044,896 to 3-C Institute For Social Development Inc. (doing business as 3C Institute), a woman-owned small business, to develop a comprehensive digital platform called FBT 2.0. The FBT 2.0 platform will deliver an integrated suite of intervention components for family-based behavioral treatment (FBT) of childhood obesity, including personalized self-paced...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $237,750 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Temple University to investigate the impact of an equity-focused implementation strategy on improving the uptake of Universal School Meals (USM) among students at high risk of food insecurity and obesity. The 2-year project, running from August 1, 2025 to July 31, 2027, aims to determine if the equity-focused implementation leads to increased USM...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $766,920 to Augusta University Research Institute, Inc. to investigate the mechanisms linking improvements in skeletal muscle metabolism to vascular health in obesity. The research aims to determine how specific changes in skeletal muscle, such as the regulation of the CYP1B1 enzyme and sarcolipin, can protect vascular function in obese...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $310,948 Project Grant to Minnesota Healthsolutions Corporation, a for-profit woman-owned small business, on September 15, 2023. The grant funds the development of an adaptable platform to support patients with behavior change interventions aimed at improving adherence to treatment and prevention for multiple chronic diseases. The platform will utilize remote...
This federal Project Grant award of $674,300, issued by the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research, supports a 3-phase study to examine the system-wide implementation of new flexibilities to the National School Lunch and Breakfast Programs (NSLP/SBP). The primary goal is to describe the impact of NSLP/SBP policy changes and flexibilities across multiple levels, and identify ways to improve the effectiveness and equity of...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $126,442 to the Regents of the University of Minnesota to conduct research on the effects of hyperglycemia and recovery on aortic growth and remodeling. The overarching objective is to determine how chronic hyperglycemia impacts aortic biomechanics and mechanobiology, and whether restoration of normoglycemia can reverse...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $865,694 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) from June 2025 to April 2029. The award aims to investigate the role of the neuropilin-2 (NRP2) receptor in regulating lymphatic function and lipid absorption, with the goal of developing novel treatments for lymphedema and obesity....
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will provide $171,450.00 to investigate the biological mechanisms linking excess body fat (adiposity) and elevated blood lipid levels, and their combined impact on cardiovascular disease risk. The research, led by Dr. Dron, a computational geneticist, aims to: 1) measure how adiposity interacts with genetic variants to influence lipid levels, 2)...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $115,949 to The Regents of the University of California, San Francisco (UCSF) to support research on the control of adipose immune-stromal niche topography in obesity. The primary objectives are to delineate adipose tissue topography using spatial sequencing, microscopy, and flow cytometry to identify novel signaling or cell...
The National Institutes of Health's National Heart, Lung and Blood Institute awarded $2,350,623 under the Cardiovascular Diseases Research program (CFDA 93.837) to the Regents of the University of Minnesota on May 1, 2021 for a project concluding on April 30, 2022. The project aims to reduce childhood obesity through an individual randomized controlled trial testing combinations of ecological momentary intervention, home visiting, and video feedback delivered to 510 low-income, racially diverse children ages 5-8 and their families. Drawing on family systems theory, the intervention will target individual and family-level behaviors related to diet quality, weight status, and weight-related behaviors. The University of Georgia Research Foundation, Inc. received a $TBD federal subaward to support this effort. The funding advances the program's goal of fostering cardiovascular research and building an expert workforce in this area through an innovative model for childhood obesity treatment in primary care.